Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Endometrial Cancer Recurrent 1Breast Neoplasms 1Advanced Cancers 1Adenocarcinoma of Lung 1ALK or ROS1-positive NSCLC 1

Interventions

Gemcitabine 2rucaparib 1romidepsin 1pembrolizumab 1enfortumab vedotin 1Trastuzumab 1Standard of Care 1Sorafenib 1Paclitaxel 1Depsipeptides 1Crizotinib 1Cisplatin 1Carboplatin 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urethral Neoplasms × Crizotinib × Clear all
NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Wake Forest University Health Sciences

Phase 2 Terminated
8 enrolled 16 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡